EMD Serono Research & Development Institute

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, EMD Serono Research & Development Institute sits in the top decile of US sponsors by registered trial count (#277 of 15,742 sponsors by registered trial count).

81 total trials 9 currently recruiting 40 completed early-phase tilt top decile by trial count

EMD Serono Research & Development Institute: 81 sponsored US clinical trials, 9 recruiting.

EMD Serono Research & Development Institute sponsors 81 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting, and 40 completed. 17 of these trials are in Phase 3-4 (later-stage) and 58 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 4 trials.

Top-decile sponsor footprint

EMD Serono Research & Development Institute ranks in the top decile of sponsors by registered trial count (#277 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

40 of 63 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

81 total, page 1 of 2

RECRUITING Phase 3

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

NCT07549412
RECRUITING Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
RECRUITING Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07332481
RECRUITING Phase 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

NCT07360314
RECRUITING Phase 1

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

NCT07166601
RECRUITING Phase 1

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132
RECRUITING Phase 1

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT06641908
RECRUITING

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891
RECRUITING Phase 1

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

NCT05464030
ACTIVE NOT RECRUITING Phase 2

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

NCT06433219
ACTIVE NOT RECRUITING Phase 1

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

NCT06421935
ACTIVE NOT RECRUITING Phase 1

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

NCT05882734
ACTIVE NOT RECRUITING Phase 2

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

NCT05327530
ACTIVE NOT RECRUITING Phase 1

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

NCT05396833
ACTIVE NOT RECRUITING Phase 1

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

NCT04170153
ACTIVE NOT RECRUITING Phase 2

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

NCT03940703
ACTIVE NOT RECRUITING Phase 3

Avelumab Program Rollover Study

NCT03815643
ACTIVE NOT RECRUITING Phase 2

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992
COMPLETED Phase 1

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

NCT07097259
TERMINATED Phase 1

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

NCT06509906
TERMINATED Phase 1

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

NCT06056310
TERMINATED Phase 2

Study of M5049 in DM and PM Participants (NEPTUNIA)

NCT05650567
TERMINATED Phase 3

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

NCT05386550
COMPLETED Phase 2

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
TERMINATED Phase 1

First in Human Study of M1069 in Advanced Solid Tumors

NCT05198349
COMPLETED Phase 3

Bintrafusp Alfa Program Rollover Study

NCT05061823
TERMINATED

Next-Gen MS: Feed-forward PRO Data for MS Research

NCT04907305
COMPLETED Phase 1

First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

NCT04882917
COMPLETED Phase 2

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

NCT04768296
COMPLETED

The MS-LINK™ Outcomes Study

NCT04735406
TERMINATED Phase 2

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

NCT04515394
COMPLETED Phase 1

M1231 in Participants With Solid Tumors

NCT04695847
COMPLETED Phase 1

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

NCT04551950
TERMINATED Phase 2

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

NCT04489940
TERMINATED Phase 3

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

NCT04459715
COMPLETED Phase 2

Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

NCT04448756
COMPLETED Phase 1

First in Human Study of M6223

NCT04457778
COMPLETED Phase 2

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

NCT04246489
TERMINATED Phase 1

First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

NCT04075721
TERMINATED Phase 2

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

NCT04066491
TERMINATED Phase 3

Study of Evobrutinib in Participants With RMS

NCT04032171
TERMINATED Phase 3

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

NCT04032158
COMPLETED Phase 4

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

NCT03961204
COMPLETED

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

NCT03933202
COMPLETED

A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)

NCT03933215
TERMINATED Phase 2

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902
COMPLETED Phase 1

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT03840915
COMPLETED Phase 2

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

NCT03833661
COMPLETED Phase 1

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

NCT03770689
COMPLETED Phase 1

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

NCT03704467
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 36
Phase 2 22
Phase 3 16
Phase 4 1

Therapeutic Areas

Advanced Solid Tumor 4
Non-Small Cell Lung Cancer 3
Metastatic or Locally Advanced Unresectable Solid Tumors 2
Solid Tumors 2
Multiple Sclerosis 2
Advanced Solid Tumors 2
Cancer 2
Locally Advanced or Metastatic Urothelial Carcinoma 1
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification 1
Relapsing Remitting Multiple Sclerosis 1

What is open in the EMD Serono Research & Development Institute pipeline

9 recruiting of 81 indexed (11% open); 40 completed (49%).

Phase mix: 17 late (III/IV) vs 58 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumor (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

EMD Serono Research & Development Institute: open-pipeline peers nationwide

Peers matched on 81 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

EMD Serono Research & Development Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080100 0%5%10%15%20%25% Total trials Recruiting share EMD Serono Research & Development InstituteThe University of Tennessee, KnoxvilleTriHealthChristiana Care Health ServicesUCB Biopharma SRLADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
EMD Serono Research & Development Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

EMD Serono Research & Development Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 81 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this EMD Serono Research & Development Institute page

81 registered trials is a research-attention snapshot, not an endorsement of EMD Serono Research & Development Institute or any single study.

  • 9 of EMD Serono Research & Development Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Advanced Solid Tumor is the condition EMD Serono Research & Development Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

EMD Serono Research & Development Institute pipeline card: 81 registered trials from official public datasets.Report a data error.